BioArctic: Eisai publishes additional detailed analyses from

STOCKHOLM, March 31, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today the publication of additional detailed analyses from the phase 2b clinical

Related Keywords

Uppsala , Uppsala Lan , Sweden , Japan , Stockholm , China , Swedish , Oskar Bosson , Translational Research , Uppsala University , Alzheimer Research , Washington University School Of Medicine , Alzheimer Network Trials Unit , Alzheimer Clinical Trial Consortium , National Institutes Of Health , European Medicines Agency , National Institute On , Drug Administration , Alzheimer Research Therapy , Devices Agency , National Medical Products Administration , Vp Communications , Ministry Of Health , Nasdaq Stockholm , Clinical Dementia Rating Sum Of Boxes , Scale Cognitive Subscale , Positron Emission Tomography , Brand Name , Clinical Trials , New England Journal , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Medical Devices Agency , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Commercialization Agreement , Nasdaq Stockholm Large Cap , Bioarctic , Disai , Ublishes , Dditional , Etailed , Analyses , Rom , Lecanemab , Hase , Study ,